It is worth noting that GCs, often administered in high doses for the treatment of graft-versus-host disease, are well known to contribute to worsening of metabolic disturbances by promoting gluconeogenesis and lipogenesis, while increasing insulin resistance [14]. The gene discussed is INS; the disease is graft versus host disease.